Building Quality into the Design and Conduct of Clinical Studies

This hybrid workshop is only a few weeks away! Seize the opportunity to network with your peers and join Duke-Margolis and the U.S. Food and Drug Administration (FDA) in person or virtually on January 31. The clinical trials community and other interested parties will gather to discuss how quality by design and risk-based monitoring approaches might be incorporated into the design and conduct of clinical studies. This event is both in person and virtual.